TY - JOUR T1 - Autoantibodies against IL-1-receptor-antagonist in multisystem inflammatory syndrome in children JF - medRxiv DO - 10.1101/2021.09.08.21263027 SP - 2021.09.08.21263027 AU - Jochen Pfeifer AU - Bernhard Thurner AU - Christoph Kessel AU - Natalie Fadle AU - Evi Regitz AU - Marie-Christin Hoffmann AU - Igor Kos AU - Klaus-Dieter Preuss AU - Yvan Fischer AU - Klaus Roemer AU - Stefan Lohse AU - Kristina Heyne AU - Marie-Claire Detemple AU - Michael Fedlmeier AU - Hendrik Juenger AU - Harald Sauer AU - Sascha Meyer AU - Tilman Rohrer AU - Helmut Wittkowski AU - Katja Masjosthusmann AU - Sören L. Becker AU - Sigrun Smola AU - Moritz Bewarder AU - Michael Boehm AU - Jordi Anton AU - Rosa Maria Pino-Ramirez AU - Hashim Abdul-Khaliq AU - Dirk Foell AU - Lorenz Thurner Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/12/2021.09.08.21263027.abstract N2 - Multisystem inflammatory syndrome in children (MIS-C or PIMS) is a rare but serious complication after an infection with SARS-CoV-2. A possible involvement of pathogenetically relevant autoantibodies has been discussed. Recently neutralizing autoantibodies against anti-inflammatory receptor antagonists progranulin (PGRN) and IL-1-receptor antagonist (IL-1-Ra) were discovered in adult patients with critical COVID-19.Plasma of an index case with severe PIMS/MIS-C was analyzed for autoantibodies against IL-1-Ra and PGRN. The study was extended by a case series of 12 additional patients. In addition to ELISA for of antibodies, IL-1-Ra plasma levels were determined and IL-1-Ra was analyzed by Western-blot and isoelectric focusing. Functional activity of the autoantibodies was examined in vitro with IL-1ß reporter assays.Antibodies against IL-1-Ra could be detected in 10 of 13 (76.9%) patients with PIMS/MIS-C, but not in controls. In contrast to critical COVID-19 in adults, no IL-1-Ra antibodies of the IgM class were detected in PIMS/MIS-C. IL-1-Ra-antibodies exclusively belonged to IgG1. No antibodies directed against PGRN were detected. Western blots and ELISA showed a concomitant reduction of free IL-1-Ra plasma levels in the presence of IL-1-Ra-antibodies. The antibodies inhibited IL-1-Ra function in IL-1ß reporter cell assays. Notably, an additional, hyperphosphorylated, transiently occurring atypical isoform of IL-1-Ra was observed in all IL-1-Ra autoantibody-positive patients.To conclude, IL-1-Ra autoantibodies were observed in high frequency in children with PIMS/MIS-C. They may represent a diagnostic and pathophysiologically relevant marker for PIMS/MIS-C. Their generation is likely to be triggered by an atypical, hyperphosphorylated isoform of IL-1-Ra.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by a grant of NanoBioMed of University of Saarland to Lorenz Thurner.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethikkommission der AErztekammer des SaarlandesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be provided upon request ER -